Key facts
- This page summarizes Adrian Rawcliffe's Form 4 filing for Adaptimmune Therapeutics PLC (ADAP).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 20 Feb 2025, 17:30.
Adrian Rawcliffe - 20 Feb 2025 Form 4 Insider Report for Adaptimmune Therapeutics PLC (ADAP)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- ADAP
- Reported as of
- 20 Feb 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 20 Feb 2025, 17:30:23 UTC
- Prior SEC filing
- 17 Jan 2025
- Next SEC filing
- 13 Aug 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Adrian George Rawcliffe
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Adrian Rawcliffe filed Form 4 for Adaptimmune Therapeutics PLC (ADAP) on 20 Feb 2025.
Change
- Previous filing in this sequence was filed on 17 Jan 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ADAP
transaction
Derivative
Option to purchase Ordinary Shares
Award
- Transaction value
- $0
- Shares
- +5,143,248
- Change %
- Price
- $0.000000
- Shares after
- 5,143,248
- Date
- 20 Feb 2025
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 5,143,248
- Exercise price
- $0.1000
- Footnotes
- F1, F2
ADAP
transaction
Derivative
Option to purchase Ordinary Shares
Award
- Transaction value
- $0
- Shares
- +3,428,832
- Change %
- Price
- $0.000000
- Shares after
- 3,428,832
- Date
- 20 Feb 2025
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 3,428,832
- Exercise price
- $0.001300
- Footnotes
- F3, F4, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
The exercise price was converted from GBP0.08 based on an exchange rate of U.S.$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount.
Footnote F2
Exercisable as to 1,285,812 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in monthly installments of 107,148 Ordinary Shares on the twentieth of each month from March 20, 2026 through January 20, 2028 and 107,256 Ordinary Shares on February 20, 2029.
Footnote F3
The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount.
Footnote F4
Exercisable as to 857,208 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in annual installments of 857,208 Ordinary Shares on the twentieth of each February from February 20, 2027 through February 20, 2029.
Footnote F5
The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.